Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus - PubMed (original) (raw)
Comparative Study
. 1993 Dec;143(6):1649-56.
Affiliations
- PMID: 8256853
- PMCID: PMC1887270
Comparative Study
Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus
Y Nakamura et al. Am J Pathol. 1993 Dec.
Abstract
Advanced glycosylation end products (AGEs) accumulate on long-lived extracellular matrix proteins and have been implicated in the micro- and macrovascular complications of diabetes mellitus. Within the arterial wall, AGE-modified proteins increase vascular permeability, inactivate nitric oxide activity, and induce the release of growth-promoting cytokines. Recently developed anti-AGE antibodies were used in an immunohistochemical analysis of coronary arteries obtained from type II diabetic and nondiabetic patients. High levels of AGE reactivity were observed within the atherosclerotic plaque present in vessels from selected patients with diabetes. Considered together with the pathological effects of AGEs on vascular wall homeostasis, these data support the role of advanced glycosylation in the rapidly progressive atherosclerosis associated with diabetes mellitus.
Similar articles
- Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus.
Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, Virmani R. Yahagi K, et al. Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):191-204. doi: 10.1161/ATVBAHA.116.306256. Epub 2016 Dec 1. Arterioscler Thromb Vasc Biol. 2017. PMID: 27908890 Free PMC article. Review. - Increased Nepsilon-(carboxymethyl)-lysine levels in cerebral blood vessels of diabetic patients and in a (streptozotocin-treated) rat model of diabetes mellitus.
van Deutekom AW, Niessen HW, Schalkwijk CG, Heine RJ, Simsek S. van Deutekom AW, et al. Eur J Endocrinol. 2008 May;158(5):655-60. doi: 10.1530/EJE-08-0024. Eur J Endocrinol. 2008. PMID: 18426823 - Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS.
Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, Polak J, Wang RZ, Ferguson K, Block C, Haas C. Seftel AD, et al. Urology. 1997 Dec;50(6):1016-26. doi: 10.1016/S0090-4295(97)00512-8. Urology. 1997. PMID: 9426743 - Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z, Sesto M, Skodlar J, Ferencak G, Turk N, Stavljenić-Rukavina A. Turk Z, et al. Horm Metab Res. 2002 Apr;34(4):196-201. doi: 10.1055/s-2002-26706. Horm Metab Res. 2002. PMID: 11987029 - Advanced glycation end products: sparking the development of diabetic vascular injury.
Goldin A, Beckman JA, Schmidt AM, Creager MA. Goldin A, et al. Circulation. 2006 Aug 8;114(6):597-605. doi: 10.1161/CIRCULATIONAHA.106.621854. Circulation. 2006. PMID: 16894049 Review.
Cited by
- Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis.
Zhang W, Yu M, Cheng G. Zhang W, et al. Front Pharmacol. 2024 Apr 17;15:1373314. doi: 10.3389/fphar.2024.1373314. eCollection 2024. Front Pharmacol. 2024. PMID: 38694909 Free PMC article. - Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study.
Chen J, Arshi B, Waqas K, Lu T, Bos D, Ikram MA, Uitterlinden AG, Kavousi M, Zillikens MC. Chen J, et al. Cardiovasc Diabetol. 2023 Nov 28;22(1):326. doi: 10.1186/s12933-023-02052-7. Cardiovasc Diabetol. 2023. PMID: 38017418 Free PMC article. Clinical Trial. - Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease.
Dozio E, Caldiroli L, Molinari P, Castellano G, Delfrate NW, Romanelli MMC, Vettoretti S. Dozio E, et al. Antioxidants (Basel). 2023 Feb 26;12(3):584. doi: 10.3390/antiox12030584. Antioxidants (Basel). 2023. PMID: 36978832 Free PMC article. Review. - Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease.
Andreadi A, Muscoli S, Tajmir R, Meloni M, Muscoli C, Ilari S, Mollace V, Della Morte D, Bellia A, Di Daniele N, Tesauro M, Lauro D. Andreadi A, et al. Int J Mol Sci. 2023 Jan 13;24(2):1646. doi: 10.3390/ijms24021646. Int J Mol Sci. 2023. PMID: 36675160 Free PMC article. Review. - Chitosan Nanoparticles in Atherosclerosis-Development to Preclinical Testing.
Sriamornsak P, Dass CR. Sriamornsak P, et al. Pharmaceutics. 2022 Apr 25;14(5):935. doi: 10.3390/pharmaceutics14050935. Pharmaceutics. 2022. PMID: 35631521 Free PMC article. Review.
References
- N Engl J Med. 1989 Apr 6;320(14):915-24 - PubMed
- Carbohydr Res. 1987 Sep 15;167:211-20 - PubMed
- Diabetes. 1957 Mar-Apr;6(2):159-67 - PubMed
- Proc Natl Acad Sci U S A. 1984 Jan;81(2):583-7 - PubMed
- Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12043-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical